Larimar Therapeutics (LRMR) Prepaid Assets (2013 - 2026)
Larimar Therapeutics' (LRMR) quarterly Prepaid Assets came in at $4.4 million in Q2 2026, down 37.36% on a YoY basis from $7.0 million in Q2 2025, and down 14.8% quarter-over-quarter from $5.2 million in Q4 2025.
Analysis
Larimar Therapeutics (LRMR) Prepaid Assets (2013 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Prepaid Assets for 14 consecutive years, with $4.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets fell 37.36% year-over-year to $4.4 million; the trailing twelve-month figure through Jun 2026 stood at $4.4 million (down 37.36% YoY), and the FY2025 full-year result was $5.2 million, down 56.37% from the prior year.
- Prepaid Assets slipped to $4.4 million in Q2 2026 per LRMR's latest filing, from $5.2 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $11.8 million in Q4 2024 and bottomed at $1.8 million in Q2 2022.
- Historically, Prepaid Assets has averaged $4.8 million across 5 years, with a median of $3.7 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Prepaid Assets jumped 250.07% in 2024, then tumbled 56.37% in 2025.
- Over 5 years, Prepaid Assets stood at $2.3 million in 2022, then surged by 46.47% to $3.4 million in 2023, then surged by 250.07% to $11.8 million in 2024, then sank by 56.37% to $5.2 million in 2025, then dropped by 14.8% to $4.4 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $4.4 million, $5.2 million, and $7.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.41 Mn |
| Dec 31, 2025 | 5.17 Mn |
| Sep 30, 2025 | 7.79 Mn |
| Jun 30, 2025 | 7.03 Mn |
| Mar 31, 2025 | 7.96 Mn |
| Dec 31, 2024 | 11.85 Mn |
| Sep 30, 2024 | 9.55 Mn |
| Jun 30, 2024 | 5.07 Mn |
| Mar 31, 2024 | 3.66 Mn |
| Dec 31, 2023 | 3.39 Mn |
| Sep 30, 2023 | 2.89 Mn |
| Jun 30, 2023 | 2.28 Mn |
| Mar 31, 2023 | 1.94 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 2.43 Mn |
| Jun 30, 2022 | 1.82 Mn |
| Mar 31, 2022 | 2.32 Mn |
| Dec 31, 2021 | 2.11 Mn |
| Sep 30, 2021 | 3.23 Mn |
| Jun 30, 2021 | 3.41 Mn |